These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14321143)

  • 41. Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin.
    Lau YC; Xiong Q; Lip GY; Blann AD
    Ann Med; 2016; 48(4):275-81. PubMed ID: 27043881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FIBTEM PLUS provides an improved thromboelastometry test for measurement of fibrin-based clot quality in cardiac surgery patients.
    Solomon C; Baryshnikova E; Schlimp CJ; Schöchl H; Asmis LM; Ranucci M
    Anesth Analg; 2013 Nov; 117(5):1054-62. PubMed ID: 24108255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Blood coagulation and fibrinolysis in venous blood after prophylactic use of antifibrinolytic agents in heart surgery with the use of xtracorporeal circulation].
    Deutschinoff A; Dimitrov D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1967; 88(2):166-73. PubMed ID: 4174654
    [No Abstract]   [Full Text] [Related]  

  • 44. ROLES OF SURFACE FACTOR AND A PLASMA INHIBITORY ACTIVITY (ANTI-SF) DURING EXPERIMENTAL THROMBOSIS IN RABBITS.
    IATRIDIS SG; IATRIDIS PG; FERGUSON JH
    Thromb Diath Haemorrh; 1964 Dec; 12():489-504. PubMed ID: 14254706
    [No Abstract]   [Full Text] [Related]  

  • 45. [Injections of tissue extracts and autologous hemolysates in the dog. Effects on the factors of hemostasis].
    Dosne AM; Josso F; Soulier JP; Lavergne JM; Malmejac J
    Nouv Rev Fr Hematol; 1968; 8(1):21-34. PubMed ID: 4232147
    [No Abstract]   [Full Text] [Related]  

  • 46. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model.
    Fries D; Innerhofer P; Reif C; Streif W; Klingler A; Schobersberger W; Velik-Salchner C; Friesenecker B
    Anesth Analg; 2006 Feb; 102(2):347-51. PubMed ID: 16428520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medium-dependent structure modifications of reconstituting fibrin.
    Belitser VA; Manjakov VP; Varetskaja TV
    Biochim Biophys Acta; 1971 Jun; 236(3):546-9. PubMed ID: 5559961
    [No Abstract]   [Full Text] [Related]  

  • 48. FIBRINOGEN BREAKDOWN PRODUCTS.
    LEWIS JH; WILSON JH
    Am J Physiol; 1964 Nov; 207():1053-7. PubMed ID: 14237449
    [No Abstract]   [Full Text] [Related]  

  • 49. Profound effects of cardiopulmonary bypass priming solutions on the fibrin part of clot formation: an ex vivo evaluation using rotation thromboelastometry.
    Brinkman AC; Romijn JW; van Barneveld LJ; Greuters S; Veerhoek D; Vonk AB; Boer C
    J Cardiothorac Vasc Anesth; 2010 Jun; 24(3):422-6. PubMed ID: 20056447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombus formation with rehydrated, lyophilized platelets.
    Fischer TH; Merricks EP; Bode AP; Bellinger DA; Russell K; Reddick R; Sanders WE; Nichols TC; Read MS
    Hematology; 2002 Dec; 7(6):359-69. PubMed ID: 12475741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. THE PLASMATIC ATMOSPHERE OF BLOOD PLATELETS. EVIDENCE THAT ONLY FIBRINOGEN, ACG, AND ACTIVATED HAGEMAN FACTOR ARE PRESENT ON THE SURFACE OF PLATELETS.
    IATRIDIS PG; FERGUSON JH
    Thromb Diath Haemorrh; 1965 Mar; 13():114-25. PubMed ID: 14285960
    [No Abstract]   [Full Text] [Related]  

  • 52. [Familial dysfibrinogenemia with abnormal nonomer aggregation. Paris III fibrinogen].
    Soria J; Soria C
    Pathol Biol (Paris); 1974 Nov; 22 suppl():72-9. PubMed ID: 4620099
    [No Abstract]   [Full Text] [Related]  

  • 53. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.
    Merskey C; Kleiner GJ; Johnson AJ
    Blood; 1966 Jul; 28(1):1-18. PubMed ID: 5944259
    [No Abstract]   [Full Text] [Related]  

  • 54. Degradation of fibrinogen by proteolytic enzymes. I. Characterization and isolation of products and their relation to fibrinolytic states.
    Sanchez-Avalos J; Miller SP
    Thromb Diath Haemorrh; 1968 Jul; 19(3):499-515. PubMed ID: 4974324
    [No Abstract]   [Full Text] [Related]  

  • 55. Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".
    Beck EA; Shainoff JR; Vogel A; Jackson DP
    J Clin Invest; 1971 Sep; 50(9):1874-84. PubMed ID: 5564395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Congenital dysfibrinogenemia. Report on a new family (fibrinogen "Wiesbaden")].
    Winckelmann G
    Thromb Diath Haemorrh Suppl; 1973; 55():345-56. PubMed ID: 4216115
    [No Abstract]   [Full Text] [Related]  

  • 57. The effect of intravascular and extravascular coagulation on serum fibrin degradation products in rats.
    Vanstone JC; Khoury NY
    Thromb Diath Haemorrh; 1971; 25(1):142-6. PubMed ID: 4996073
    [No Abstract]   [Full Text] [Related]  

  • 58. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry.
    Ogawa S; Szlam F; Bolliger D; Nishimura T; Chen EP; Tanaka KA
    Anesth Analg; 2012 Jul; 115(1):16-21. PubMed ID: 22467887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrinogen C-terminal peptidic sequences (Haptides) modulate fibrin polymerization.
    Marx G; Ben-Moshe M; Magdassi S; Gorodetsky R
    Thromb Haemost; 2004 Jan; 91(1):43-51. PubMed ID: 14691567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombosis-associated antifibrinogen IgG1 κ impairs fibrin polymerization and enhances platelet activation.
    Galanakis DK; Spitzer ED; Perrotta P; Nagaswami C; Marchi R; Spitzer S; Refailovich M; Smith RE; Zhang L; Marmorat C; Weisel JW
    Blood Coagul Fibrinolysis; 2017 Jan; 28(1):40-49. PubMed ID: 26849715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.